Celrixafor

Celrixafor is a generic formulation of plerixafor, a small molecule CXCR4 antagonist. It is being evaluated by the Hospital Universitario Dr. Jose E. Gonzalez for its efficacy in mobilizing hematopoietic stem cells (HSCs) into the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma. The drug works by blocking the interaction between C-X-C motif chemokine ligand 12 (CXCL12), also known as stromal cell-derived factor-1 (SDF-1), and its receptor, CXCR4. This disruption releases HSCs from the bone marrow niche into the systemic circulation, facilitating their harvest for stem cell transplants. The specific clinical focus for Celrixafor involves evaluating the efficacy of a reduced-dose regimen compared to standard dosing or placebo.

Brand names

Celrixafor

Other names

generic plerixafor